Results 71 to 80 of about 15,396 (182)

The New Era of Pneumococcal Vaccination in Adults: What Is Next?

Vaccines
Streptococcus pneumoniae remains the leading cause of community-acquired pneumonia in adults and bacterial meningitis in children worldwide. In addition to pneumonia, invasive pneumococcal diseases (IPDs), such as bacteremia and meningitis, pose a ...
Lale Ozisik
doaj   +1 more source

Update on the success of the pneumococcal conjugate vaccine

Paediatrics & Child Health, 2011
Several years after the seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in Canada and elsewhere, routine infant vaccination has led to near eradication of invasive pneumococcal disease caused by vaccine serotype strains in both children and adults.
openaire   +2 more sources

Experience with pneumococcal conjugate vaccine in Norway

Expert Review of Vaccines, 2009
Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced into the Norwegian childhood vaccination program in July 2006 in a 2+1 dose (three-dose) schedule. Vaccine coverage quickly reached high levels and the incidence rate of invasive pneumococcal disease in children under 2 years of age declined rapidly.
openaire   +2 more sources

Pneumococcal conjugate vaccines—a European perspective

International Journal of Medical Microbiology, 2004
Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and acute otitis media in children and adults worldwide. In the age group of < 2 years the incidence of invasive pneumococcal disease ranges from approximately 14 cases per 100,000 in Germany and the Netherlands and more than 90 per 100,000 children in Spain.
openaire   +2 more sources

Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis

Health Technology Assessment
Background Vaccination of infants with pneumococcal conjugate vaccines is recommended by the World Health Organization. Evidence is mixed regarding the differences in immunogenicity and efficacy of the different pneumococcal vaccines.
Shuo Feng, Julie McLellan, Nicola Pidduck, Nia Roberts, Julian PT Higgins, Yoon Choi, Alane Izu, Mark Jit, Shabir A Madhi, Kim Mulholland, Andrew J Pollard, Simon Procter, Beth Temple, Merryn Voysey   +13 more
doaj   +1 more source

Adult Pneumococcal Vaccination in Latin America: The Next Step Beyond Pediatric Pneumococcal Conjugate Vaccine. [PDF]

Cureus
Zavaleta-Monestel E, Arguedas-Chacón S, Mora-Jiménez J, Díaz-Madriz JP, Herrera-Jiménez LG.   +4 more
europepmc   +1 more source

Clonal expansion of global pneumococcal sequence cluster 3 within serotype 8 after 13-valent pneumococcal conjugate vaccine introduction, South Africa. [PDF]

Microb Genom
Lekhuleni C, Ndlangisa K, Sanches Ferreira AD, Cheng HR, Lorenz O, Kleynhans J, de Gouveia L, Skosana H, Quan V, Cremers AJH, Hawkins PA, Chochua S, McGee L, Bentley SD, Meiring S, Cohen C, Lo SW, von Gottberg A, du Plessis M.   +18 more
europepmc   +1 more source

Impact of a 21-valent pneumococcal conjugate vaccine on pneumococcal disease incidence among adults 65-84 years of age in Belgium: An epidemiological modeling study. [PDF]

Hum Vaccin Immunother
Vandenplas Y, Dobbelaere J, Tsoumani E, Oidtman R, Lang JC, Meleleo G, Sharomi O.   +6 more
europepmc   +1 more source

Serotype-specific pneumococcal conjugate vaccine effectiveness in Canadian children: an indirect cohort study using Bayesian hierarchical modeling of multisite data. [PDF]

BMC Infect Dis
Zhou Z, Deceuninck G, Brousseau N, McGeer A, Naus M, Kellner JD, Sell H, Sadarangani M, De Wals P.   +8 more
europepmc   +1 more source

Inequalities in childhood pneumococcal conjugate vaccine uptake in England before and after the change from a 2 + 1 to 1 + 1 schedule: a longitudinal study. [PDF]

Lancet Reg Health Eur
Ilechukwu P, Hungerford D, French N, Hill EM.   +3 more
europepmc   +1 more source